PLCG2 — gene · CancerIndex

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PLCG2 D1140E1
Venetoclax	Chronic Lymphocytic Leukemia	Predictive	C	Supports Resistance	2	submitted	EID10372 The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC	civic
PLCG2 MUTATION1
(prognostic)	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	5	accepted	EID5834 Whole exome sequencing was performed on baseline and relapse samples from six patients with CLL. One relapse sample had mutations in BTK and PLCG2, and a second relapse sample only had a mutation in … (full text at CIViC) PMID ·

Cohorts

Alteration frequency by cohort (98)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved98 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial and Ovarian Cancer (MSK, Nature Medicine 2024) ucec_msk_2024	unmapped	Ssm	6	33

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
· N Engl J Med · 2014 · PMID 24869598 · validated civic_curation pubmed